EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial

Yu-Hao Lin iD, Zhi-Jun Zhang, Jin-Qing Zhong, Zhi-Yi Wang, Yi-Ting Peng, Yan-Mei Lin, Huo-Ping Zhang, Jian-Qing Tian

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0302155 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Yu-Hao Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glucosides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical and Health Guidance Projects of Xiamen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonalcoholic fatty liver disease (NAFLD) is strongly associated with type 2 diabetes mellitus (T2DM). Lifestyle intervention remains a preferred treatment modality for NAFLD. The glucagon-like peptide (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been developed as new glucose-lowering drugs, which can improve fatty liver via an insulin-independent glucose-lowering effect. However, studies exploring the efficacy of GLP-1 receptor agonists combined with SGLT-2 inhibitors in patients with NAFLD and T2DM are scanty. Thus, the present randomised controlled trial aims at comparing the efficacy and safety of semaglutide plus empagliflozin with each treatment alone in patients with NAFLD and T2DM.

Methods

This 52-week double-blinded, randomised, parallel-group, active-controlled trial evaluates the effects of semaglutide, empagliflozin and semaglutide + empagliflozin in 105 eligible overweight/obese subjects with NAFLD and T2DM. The primary outcome will be a change from baseline to week 52 in the controlled attenuation parameter, free fatty acid and glucagon. Secondary endpoints include changes in liver stiffness measurement, liver enzymes, blood glucose, lipid levels, renal function, electrolyte balances, minerals and bone metabolism, cytokines, high-sensitivity C-reactive protein, ferritin, anthropometric indicators, nonalcoholic fatty liver fibrosis score, fibrosis 4 score and homeostatic model assessment for insulin resistance. In addition, intention-to-treat, interim analysis and safety analysis will be performed.

Discussion

This double-blinded, randomised, clinical trial involves a multi-disciplinary approach and aims to explore the synergistic effects of the combination of semaglutide and empagliflozin. The results can provide important insights into mechanisms of GLP-1 receptor agonists and/or SGLT-2 inhibitors in patients with NAFLD and T2DM.

Trial registration

This study has been registered with Chinese Clinical Trial Registry ( ChiCTR2300070674 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsDiabetes Mellitus, Type 2Glucagon-Like PeptidesGlucosidesNon-alcoholic Fatty Liver DiseaseAdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseDouble-Blind MethodDrug Therapy, CombinationHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsTreatment OutcomeRandomized Controlled Trials as TopicSemaglutide

Substanzen

Benzhydryl CompoundsBlood GlucoseGlucagon-Like PeptidesGlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsSemaglutideempagliflozin

Autor:innen und Institutionen

  • Department of Endocrinology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China.
  • Department of Laboratory Medicine, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China.
  • Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, Fujian, China.
  • Department of Ultrasound, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China.

ORCID-Profile: Yu-Hao Lin

Förderung

  • Medical and Health Guidance Projects of Xiamen

Zitieren

APA

Lin, Y. H., Zhang, Z. J., Zhong, J. Q., Wang, Z. Y., Peng, Y. T., Lin, Y. M., Zhang, H. P., & Tian, J. Q. (2024). Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0302155

Vancouver

Lin YH, Zhang ZJ, Zhong JQ, Wang ZY, Peng YT, Lin YM, et al. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0302155

BibTeX
@article{Lin2024,
  author = {Lin, Yu-Hao and Zhang, Zhi-Jun and Zhong, Jin-Qing and Wang, Zhi-Yi and Peng, Yi-Ting and Lin, Yan-Mei and Zhang, Huo-Ping and Tian, Jian-Qing},
  title = {Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0302155}
}
Kostenlos starten →